Accueil>>Signaling Pathways>> Cardiovascular>> Vasoconstriction>>Desglymidodrine

Desglymidodrine (Synonyms: ST 1059)

Catalog No.GC52051

La desglymidodrine (ST 1059), le métabolite actif de la midodrine, est un agoniste sélectif des récepteurs α1-adrénergiques.

Products are for research use only. Not for human use. We do not sell to patients.

Desglymidodrine Chemical Structure

Cas No.: 3600-87-1

Taille Prix Stock Qté
1 mg
46,00 $US
En stock
5 mg
138,00 $US
En stock
10 mg
230,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Desglymidodrine is the active metabolite of the prodrug midodrine .1 It is formed from midodrine by enzymatic hydrolysis.2 Desglymidodrine is an agonist of α1-adrenergic receptors (α1-ARs).1 It binds to α1-ARs (Kis = 9.77, 9.55, and 8.51 µM for α1A, α1B, and α1D-ARs, respectively) and increases intraurethral pressure (IUP) and mean arterial pressure (MAP) by 5 and 20 mm Hg, respectively, in anesthetized dogs at doses of 205 and 250 nmol/kg, respectively.

1.Altenbach, R.J., Khilevich, A., Kolasa, T., et al.Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing α1A-adrenoceptor agonistJ. Med. Chem.47(12)3220-3235(2004) 2.McClellan, K.J., Wiseman, L.R., and Wilde, M.I.Midodrine. A review of its therapeutic use in the management of orthostatic hypotensionDrugs Aging12(1)76-86(1998)

Avis

Review for Desglymidodrine

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Desglymidodrine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.